Alexandra E Grier
Overview
Explore the profile of Alexandra E Grier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
153
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Grier A, McGill J, Lord S, Speake C, Greenbaum C, Chamberlain C, et al.
AACE Clin Case Rep
. 2023 Jul;
9(4):101-103.
PMID: 37520758
Background: Identifying cases of diabetes caused by single gene mutations between the more common type 1 diabetes (T1D) and type 2 diabetes (T2D) is a difficult but important task. We...
2.
Hale M, Lee B, Honaker Y, Leung W, Grier A, Jacobs H, et al.
Mol Ther Methods Clin Dev
. 2017 Mar;
4:192-203.
PMID: 28345004
Gene editing by homology-directed recombination (HDR) can be used to couple delivery of a therapeutic gene cassette with targeted genomic modifications to generate engineered human T cells with clinically useful...
3.
Gwiazda K, Grier A, Sahni J, Burleigh S, Martin U, Yang J, et al.
Mol Ther
. 2016 May;
24(9):1570-80.
PMID: 27203437
Many future therapeutic applications of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 and related RNA-guided nucleases are likely to require their use to promote gene targeting, thus necessitating development of...
4.
Grier A, Burleigh S, Sahni J, Clough C, Cardot V, Choe D, et al.
Mol Ther Nucleic Acids
. 2016 Apr;
5:e306.
PMID: 27093168
Increasing demand for large-scale synthesis of in vitro transcribed (IVT) mRNA is being driven by the increasing use of mRNA for transient gene expression in cell engineering and therapeutic applications....
5.
Presa M, Chen Y, Grier A, Leiter E, Brehm M, Greiner D, et al.
J Immunol
. 2015 Aug;
195(7):3011-9.
PMID: 26283479
NOD-scid.Il2rg(null) (NSG) mice are currently being used as recipients to screen for pathogenic autoreactive T cells in type 1 diabetes (T1D) patients. We questioned whether the restriction of IL-2R γ-chain...
6.
Niens M, Grier A, Marron M, Kay T, Greiner D, Serreze D
Diabetes
. 2011 Feb;
60(4):1229-36.
PMID: 21346176
Objective: Type 1 diabetes can be inhibited in standard NOD mice by autoantigen-specific immunotherapy targeting pathogenic CD8+ T-cells. NOD.β2m(null).HHD mice expressing human HLA-A2.1 but lacking murine major histocompatibility complex class...
7.
Driver J, Scheuplein F, Chen Y, Grier A, Wilson S, Serreze D
Diabetes
. 2009 Nov;
59(2):423-32.
PMID: 19903740
Objective: In part, activation of invariant natural killer T (iNKT)-cells with the superagonist alpha-galactosylceramide (alpha-GalCer) inhibits the development of T-cell-mediated autoimmune type 1 diabetes in NOD mice by inducing the...
8.
Serreze D, Choisy-Rossi C, Grier A, Holl T, Chapman H, Gahagan J, et al.
J Immunol
. 2008 Feb;
180(5):3250-9.
PMID: 18292549
When expressed in NOD, but not C57BL/6 (B6) genetic background mice, the common class I variants encoded by the H2g7 MHC haplotype aberrantly lose the ability to mediate the thymic...